INVA

Innoviva Inc

Add to Watchlist

Advanced Chart

18.580

+0.250(+1.360%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

18.750

Open

18.280

VWAP

18.62

Vol

818.85K

Mkt Cap

1.17B

Low

18.130

Amount

15.24M

EV/EBITDA(TTM)

5.18

Total Shares

62.44M

1.15B

EV/OCF(TTM)

5.76

P/S(TTM)

3.67

Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA. The Company's products include GIAPREZA and XERAVA. GIAPREZA (angiotensin II) injection is approved by the United States Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAV (eravacycline) for injection is approved by the United States FDA and Singapore Health Sciences Authority (HSA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q1

FY2025Q2

FY2025Q3

80.25M

+3.55%

0.380

-17.39%

87.10M

-12.81%

0.430

-178.18%

91.60M

+2.34%

0.480

+306.09%

Estimates Revision

The market is revising No Change the revenue expectations for Innoviva, Inc. (INVA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 3.05%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+3.05%

In Past 3 Month

1 Analyst Rating

196.02% Upside

Wall Street analysts forecast INVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INVA is 55.00 USD with a low forecast of 55.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

196.02% Upside

Current: 18.580

Low

55.00

Averages

55.00

High

55.00

196.02% Upside

Current: 18.580

Low

55.00

Averages

55.00

High

55.00

Scotiabank

Louise Chen

Buy

Initiates

$55

2025-03-07

Reason

Scotiabank

Louise Chen

Price Target

$55

2025-03-07

Initiates

Buy

Reason

Scotiabank initiated coverage of Innoviva with an Outperform rating and $55 price target. Innoviva's stock has been overlooked because its value proposition is not explicitly clear, but bolder moves to maximize shareholder value could be coming, including new launches, expanding the Innoviva Specialty Therapeutics platform, and monetizing non-core assets, the analyst tells investors in a research note. The stock also looks interesting in a tough capital markets environment because it is profitable and has historically been successful at consolidating undervalued assets, the firm argues.

Cantor Fitzgerald

Louise Chen

Buy

Reiterates

n/a

2024-08-01

Reason

Cantor Fitzgerald

Louise Chen

Price Target

n/a

2024-08-01

Reiterates

Buy

Reason

Cantor Fitzgerald

Louise Chen

Buy

Reiterates

n/a

2024-07-30

Reason

Cantor Fitzgerald

Louise Chen

Price Target

n/a

2024-07-30

Reiterates

Buy

Reason

Cantor Fitzgerald

Louise Chen

Buy

Reiterates

n/a

2024-06-20

Reason

Cantor Fitzgerald

Louise Chen

Price Target

n/a

2024-06-20

Reiterates

Buy

Reason

Cantor Fitzgerald

Louise Chen

Buy

Initiates

n/a

2024-06-18

Reason

Cantor Fitzgerald

Louise Chen

Price Target

n/a

2024-06-18

Initiates

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Innoviva Inc (INVA.O) is 15.63, compared to its 5-year average forward P/E of 11.36. For a more detailed relative valuation and DCF analysis to assess Innoviva Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

11.36

Current PE

15.63

Overvalued PE

17.53

Undervalued PE

5.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

7.58

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

9.53

Undervalued EV/EBITDA

5.62

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

3.74

Current PS

3.00

Overvalued PS

4.82

Undervalued PS

2.65